50 Studies Every Hospitalist Should Know
Herausgeber: Geisler, Benjamin P; Greenwald, Jeffrey L; Tran, Kathy May
50 Studies Every Hospitalist Should Know
Herausgeber: Geisler, Benjamin P; Greenwald, Jeffrey L; Tran, Kathy May
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Hospital medicine is rapidly growing, driven by the patient safety movement and the increasing complexity of diagnosing and treating acutely ill patients. The field has expanded significantly, with around 52,000 hospitalists in the U.S., including nurse practitioners and physician assistants. These professionals face numerous diagnostic tests, extensive data on treatment options for complex patients, and administrative pressure to improve care quality while controlling costs. Pay-for-performance incentives further emphasize the need for current evidence-based management. Specialty societies…mehr
Hospital medicine is rapidly growing, driven by the patient safety movement and the increasing complexity of diagnosing and treating acutely ill patients. The field has expanded significantly, with around 52,000 hospitalists in the U.S., including nurse practitioners and physician assistants. These professionals face numerous diagnostic tests, extensive data on treatment options for complex patients, and administrative pressure to improve care quality while controlling costs. Pay-for-performance incentives further emphasize the need for current evidence-based management. Specialty societies and the US Preventive Services Task Force provide evidence-based guidelines for clinical care. However, managing individual patients often requires detailed knowledge of key studies to determine if guidelines or meta-analyses are applicable. Understanding study populations and treatment effect sizes is crucial for making personalized management decisions and guiding patients and caregivers. 50 Studies Every Hospitalist Should Know introduces readers to pivotal articles that impact daily clinical practice and inform management recommendations. The book highlights essential details of each study, helping readers assess strengths and limitations not evident in guidelines and reviews. This knowledge aids providers in selecting therapeutic strategies and advising patients and families. The selected studies are high-yield and relevant to hospitalists' everyday decisions. The book is also a valuable teaching tool for trainees, illustrating evidence-based medicine and its application to patient cases.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press
- Seitenzahl: 408
- Erscheinungstermin: 17. Februar 2026
- Englisch
- Gewicht: 5g
- ISBN-13: 9780190937126
- ISBN-10: 0190937122
- Artikelnr.: 67732384
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Oxford University Press
- Seitenzahl: 408
- Erscheinungstermin: 17. Februar 2026
- Englisch
- Gewicht: 5g
- ISBN-13: 9780190937126
- ISBN-10: 0190937122
- Artikelnr.: 67732384
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Benjamin P. Geisler is a hospitalist at Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School. Throughout his career, he has worked in various roles on health-economic evaluations, systematic reviews and with real world evidence such as population-based health registries. Dr. Geisler has also worked on quality and safety topics, as well as in a research group that focuses on machine learning and artificial intelligence. Dr. Geisler's career interest is the interface between new health technologies, their evidence base, and value. Jeffrey L. Greenwald is an academic hospitalist at Massachusetts General Hospital whose career has taken him into the fields of HIV testing, care transitions, quality improvement and patient safety, medical education, and, for the last several years, primary palliative care education and implementation. He is an active clinician and teacher and an Associate Professor at Harvard Medical School. Kathy May Tran is an academic hospitalist at the Massachusetts General Hospital, teacher at Harvard Medical School, and Associate Editor of the Case Records of the New England Journal of Medicine. In addition to her identities as an active clinician, medical educator, and writer and editor, Dr. Tran is an advocate for workforce well-being, patient experience, and the arts and humanities in medicine.
* SECTION 1: NEUROLOGY and PSYCHIATRY
* Chapter 1 Detecting delirium: The CAM study
* Benjamin P. Geisler, MD, MPH
* Chapter 2 Delirium prevention in older hospitalized patients: The
Elder Life Program Trial
* Mobola Campbell, MD, MPH, MEd
* Chapter 3 Patent foramen ovale closure for cryptogenic stroke: The
REDUCE Trial
* Hugo Torres, MD, MPH
* Chapter 4 Thrombolysis timing in acute ischemic stroke: The ECASS III
Trial
* Jillian M. Berkman, MD and Mark Etherton, MD, PhD
* Chapter 5 Symptom-triggered vs fixed-schedule benzodiazepines for
alcohol withdrawal
* Rahul B. Ganatra, MD, MPH
* Chapter 6 Education and naloxone distribution to prevent opioid
overdoses
* Victoria D. Powell, MD and Pooja Lagisetty, MD
* SECTION 2: CARDIOLOGY
* Chapter 7 Peri-operative risk for myocardial infarction or cardiac
arrest
* Jeffrey L. Greenwald, MD
* Chapter 8 Perioperative beta blockers for non-cardiac surgery
* Jeffrey L. Greenwald, MD
* Chapter 9 Heparin vs. enoxaparin for unstable coronary artery
disease: The ESSENCE trial
* Bradford A. Hilson, MD
* Chapter 10 Early invasive management for non-ST segment elevation
acute coronary syndrome: The TACTICS-TIMI-18 Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 11 Dual antiplatelet therapy for non-ST segment elevation
acute coronary syndromes: The Cure Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 12 Intensive vs moderate-intensity statins after acute
coronary syndromes: The PROVE IT-TIMI 22 Trial
* Nilay K. Patel, MD
* Chapter 13 Loop diuretics for decompensated heart failure: The DOSE
Study
* Debbie Lin Teodorescu, MD, MEng, AM and Hugo Torres, MD, MPH
* Chapter 14 Angiotensin receptor-neprilysin inhibition in heart
failure: The PARADIGM-HF Trial
* Peyton Hanson, MD and Kathleen M. Finn MD, MPhil
* Chapter 15 Estimating risk of stroke in atrial fibrillation: The
CHADS2 Trial
* Yichi Zhang MD, MBA, Christopher S. Schenck, MD, and David M.
Dudzinski, MD
* Chapter 16 Apixaban vs. warfarin for atrial fibrillation: The
ARISTOTLE trial
* Priyank Jain, MBBS
* SECTION 3: PULMONOLOGY and CRITICAL CARE
* Chapter 17 Procalcitonin-guided antibiotic use in lower respiratory
tract infection
* Philipp Schuetz, MD, MPH
* Chapter 18 Early discontinuation of antibiotics for
community-acquired pneumonia
* Kathy May Tran, MD
* Chapter 19 Glucocorticoids in exacerbations of chronic obstructive
pulmonary disease: The REDUCE Trial
* Mobola Campbell, MD, MPH, MEd and Jeffrey L. Greenwald, MD
* Chapter 20 Noninvasive ventilation for exacerbations of chronic
obstructive pulmonary disease
* Raymond C. Parrish II, MD
* Chapter 21 Clinical criteria and D-dimer to exclude pulmonary
embolism: The Wells Criteria
* Jeffrey L. Greenwald, MD
* Chapter 22 Point-of-care ultrasound in acute respiratory failure: The
BLUE Protocol
* Thomas F. Heyne, MD, MSt and Kathy May Tran, MD
* Chapter 23 Low tidal volume ventilation in acute respiratory distress
syndrome: The ARMA Trial
* Raymond C. Parrish II, MD
* Chapter 24 Fluid management in acute respiratory distress syndrome:
The FACTT Trial
* Dominik J. Hoechter, MD
* Chapter 25 Dopamine vs. norepinephrine for shock: The SOAP II Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 26 Protocol-based care for septic shock: The ProCESS Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 27 Targeted temperature management after cardiac arrest: The
TTM Trial
* Christy N. Taylor, MD, MPH and Jonathan Ludmir, MD
* SECTION 4: GASTROENTEROLOGY
* Chapter 28 Fecal transplant for recurrent Clostridiodes difficile
infection
* Farrin A. Manian, MD, MPH
* Chapter 29 Antibiotic prophylaxis in cirrhosis and upper
gastrointestinal bleeding
* Farrin A. Manian, MD, MPH
* Chapter 30 Endoscopic variceal ligation and nadolol to prevent
variceal rebleeding
* Rahul B. Ganatra, M.D., MPH
* Chapter 31 Albumin for spontaneous bacterial peritonitis in cirrhosis
* Bradford A. Hilson, MD
* SECTION 5: HEMATOLOGY and ONCOLOGY
* Chapter 32 Risk for venous thromboembolism in hospitalized patients:
The Padua Prediction Score
* Rahul B. Ganatra, MD, MPH
* Chapter 33 Low-molecular weight vs. unfractionated heparin for
pulmonary embolism
* William C. Hillmann, MD, MS
* Chapter 34 Low-molecular weight heparin vs. oral vitamin K antagonist
for cancer-associated venous thromboembolism: The CLOT Trial
* Marko Velimirovic, MD, MMSc and Hugo Torres, MD, MPH
* Chapter 35 Perioperative anticoagulation for atrial fibrillation: The
BRIDGE Trial
* Priyank Jain, MBBS
* Chapter 36 Bleeding risk from anticoagulation in atrial fibrillation:
HAS-BLED
* Jeffrey L. Greenwald, MD
* Chapter 37 Transfusion thresholds in critically ill patients: The
TRICC Trial
* Jeffrey L. Greenwald, MD
* Chapter 38 4 T's Score to exclude heparin-induced thrombocytopenia
* Jeffrey L. Greenwald, MD
* Chapter 39 Early palliative care for metastatic cancer
* Mobola Campbell, MD, MPH, MEd and Kathy May Tran, MD
* SECTION 6: FLUIDS, NUTRITION, and METABOLISM
* Chapter 40 Timing of parenteral nutrition in critically ill patients:
The EPaNIC Study
* Mobola Campbell, MD, MPH, MEd and Katharine E. Black, M.D.
* Chapter 41 Early nasoenteric tube feeding in acute pancreatitis: The
PYTHON Trial
* Margaret M. Chapman, MD
* Chapter 42 Glucose control in critically ill patients: The NICE-SUGAR
Trial
* Hugo Torres, MD, MPH
* Chapter 43 Zoledronic acid after hip fracture: The HORIZON-RFT Trial
* Hugo Torres, MD, MPH and Kathy May Tran, MD
* SECTION 7: HOSPITAL SYSTEMS and OPERATIONS
* Chapter 44 Unconscious bias in referrals for cardiac catheterization
* William J. Tate, MD and Sherri-Ann M. Burnett-Bowie, MD, MPH
* Chapter 45 Replacing indwelling urinary catheters for urinary tract
infection
* Hugo Torres, MD, MPH
* Chapter 46 Financial impact of healthcare-associated infections
* Marc Philip T. Pimentel, MD, MPH
* Chapter 47 Pharmacist-guided medication reconciliation to reduce
readmissions
* Hugo Torres, MD, MPH
* Chapter 48 Patient-targeted discharge education to prevent heart
failure readmissions
* Aditya Achanta, MD and Jason H. Wasfy, MD, MPhil
* Chapter 49 Identifying preventable 30-day hospital readmissions
* Hugo Torres, MD, MPH and Jeffrey L. Greenwald, MD
* Chapter 50 Effect of hospitalist care on medical utilization
* Anand Kartha, MD, MS
* Chapter 1 Detecting delirium: The CAM study
* Benjamin P. Geisler, MD, MPH
* Chapter 2 Delirium prevention in older hospitalized patients: The
Elder Life Program Trial
* Mobola Campbell, MD, MPH, MEd
* Chapter 3 Patent foramen ovale closure for cryptogenic stroke: The
REDUCE Trial
* Hugo Torres, MD, MPH
* Chapter 4 Thrombolysis timing in acute ischemic stroke: The ECASS III
Trial
* Jillian M. Berkman, MD and Mark Etherton, MD, PhD
* Chapter 5 Symptom-triggered vs fixed-schedule benzodiazepines for
alcohol withdrawal
* Rahul B. Ganatra, MD, MPH
* Chapter 6 Education and naloxone distribution to prevent opioid
overdoses
* Victoria D. Powell, MD and Pooja Lagisetty, MD
* SECTION 2: CARDIOLOGY
* Chapter 7 Peri-operative risk for myocardial infarction or cardiac
arrest
* Jeffrey L. Greenwald, MD
* Chapter 8 Perioperative beta blockers for non-cardiac surgery
* Jeffrey L. Greenwald, MD
* Chapter 9 Heparin vs. enoxaparin for unstable coronary artery
disease: The ESSENCE trial
* Bradford A. Hilson, MD
* Chapter 10 Early invasive management for non-ST segment elevation
acute coronary syndrome: The TACTICS-TIMI-18 Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 11 Dual antiplatelet therapy for non-ST segment elevation
acute coronary syndromes: The Cure Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 12 Intensive vs moderate-intensity statins after acute
coronary syndromes: The PROVE IT-TIMI 22 Trial
* Nilay K. Patel, MD
* Chapter 13 Loop diuretics for decompensated heart failure: The DOSE
Study
* Debbie Lin Teodorescu, MD, MEng, AM and Hugo Torres, MD, MPH
* Chapter 14 Angiotensin receptor-neprilysin inhibition in heart
failure: The PARADIGM-HF Trial
* Peyton Hanson, MD and Kathleen M. Finn MD, MPhil
* Chapter 15 Estimating risk of stroke in atrial fibrillation: The
CHADS2 Trial
* Yichi Zhang MD, MBA, Christopher S. Schenck, MD, and David M.
Dudzinski, MD
* Chapter 16 Apixaban vs. warfarin for atrial fibrillation: The
ARISTOTLE trial
* Priyank Jain, MBBS
* SECTION 3: PULMONOLOGY and CRITICAL CARE
* Chapter 17 Procalcitonin-guided antibiotic use in lower respiratory
tract infection
* Philipp Schuetz, MD, MPH
* Chapter 18 Early discontinuation of antibiotics for
community-acquired pneumonia
* Kathy May Tran, MD
* Chapter 19 Glucocorticoids in exacerbations of chronic obstructive
pulmonary disease: The REDUCE Trial
* Mobola Campbell, MD, MPH, MEd and Jeffrey L. Greenwald, MD
* Chapter 20 Noninvasive ventilation for exacerbations of chronic
obstructive pulmonary disease
* Raymond C. Parrish II, MD
* Chapter 21 Clinical criteria and D-dimer to exclude pulmonary
embolism: The Wells Criteria
* Jeffrey L. Greenwald, MD
* Chapter 22 Point-of-care ultrasound in acute respiratory failure: The
BLUE Protocol
* Thomas F. Heyne, MD, MSt and Kathy May Tran, MD
* Chapter 23 Low tidal volume ventilation in acute respiratory distress
syndrome: The ARMA Trial
* Raymond C. Parrish II, MD
* Chapter 24 Fluid management in acute respiratory distress syndrome:
The FACTT Trial
* Dominik J. Hoechter, MD
* Chapter 25 Dopamine vs. norepinephrine for shock: The SOAP II Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 26 Protocol-based care for septic shock: The ProCESS Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 27 Targeted temperature management after cardiac arrest: The
TTM Trial
* Christy N. Taylor, MD, MPH and Jonathan Ludmir, MD
* SECTION 4: GASTROENTEROLOGY
* Chapter 28 Fecal transplant for recurrent Clostridiodes difficile
infection
* Farrin A. Manian, MD, MPH
* Chapter 29 Antibiotic prophylaxis in cirrhosis and upper
gastrointestinal bleeding
* Farrin A. Manian, MD, MPH
* Chapter 30 Endoscopic variceal ligation and nadolol to prevent
variceal rebleeding
* Rahul B. Ganatra, M.D., MPH
* Chapter 31 Albumin for spontaneous bacterial peritonitis in cirrhosis
* Bradford A. Hilson, MD
* SECTION 5: HEMATOLOGY and ONCOLOGY
* Chapter 32 Risk for venous thromboembolism in hospitalized patients:
The Padua Prediction Score
* Rahul B. Ganatra, MD, MPH
* Chapter 33 Low-molecular weight vs. unfractionated heparin for
pulmonary embolism
* William C. Hillmann, MD, MS
* Chapter 34 Low-molecular weight heparin vs. oral vitamin K antagonist
for cancer-associated venous thromboembolism: The CLOT Trial
* Marko Velimirovic, MD, MMSc and Hugo Torres, MD, MPH
* Chapter 35 Perioperative anticoagulation for atrial fibrillation: The
BRIDGE Trial
* Priyank Jain, MBBS
* Chapter 36 Bleeding risk from anticoagulation in atrial fibrillation:
HAS-BLED
* Jeffrey L. Greenwald, MD
* Chapter 37 Transfusion thresholds in critically ill patients: The
TRICC Trial
* Jeffrey L. Greenwald, MD
* Chapter 38 4 T's Score to exclude heparin-induced thrombocytopenia
* Jeffrey L. Greenwald, MD
* Chapter 39 Early palliative care for metastatic cancer
* Mobola Campbell, MD, MPH, MEd and Kathy May Tran, MD
* SECTION 6: FLUIDS, NUTRITION, and METABOLISM
* Chapter 40 Timing of parenteral nutrition in critically ill patients:
The EPaNIC Study
* Mobola Campbell, MD, MPH, MEd and Katharine E. Black, M.D.
* Chapter 41 Early nasoenteric tube feeding in acute pancreatitis: The
PYTHON Trial
* Margaret M. Chapman, MD
* Chapter 42 Glucose control in critically ill patients: The NICE-SUGAR
Trial
* Hugo Torres, MD, MPH
* Chapter 43 Zoledronic acid after hip fracture: The HORIZON-RFT Trial
* Hugo Torres, MD, MPH and Kathy May Tran, MD
* SECTION 7: HOSPITAL SYSTEMS and OPERATIONS
* Chapter 44 Unconscious bias in referrals for cardiac catheterization
* William J. Tate, MD and Sherri-Ann M. Burnett-Bowie, MD, MPH
* Chapter 45 Replacing indwelling urinary catheters for urinary tract
infection
* Hugo Torres, MD, MPH
* Chapter 46 Financial impact of healthcare-associated infections
* Marc Philip T. Pimentel, MD, MPH
* Chapter 47 Pharmacist-guided medication reconciliation to reduce
readmissions
* Hugo Torres, MD, MPH
* Chapter 48 Patient-targeted discharge education to prevent heart
failure readmissions
* Aditya Achanta, MD and Jason H. Wasfy, MD, MPhil
* Chapter 49 Identifying preventable 30-day hospital readmissions
* Hugo Torres, MD, MPH and Jeffrey L. Greenwald, MD
* Chapter 50 Effect of hospitalist care on medical utilization
* Anand Kartha, MD, MS
* SECTION 1: NEUROLOGY and PSYCHIATRY
* Chapter 1 Detecting delirium: The CAM study
* Benjamin P. Geisler, MD, MPH
* Chapter 2 Delirium prevention in older hospitalized patients: The
Elder Life Program Trial
* Mobola Campbell, MD, MPH, MEd
* Chapter 3 Patent foramen ovale closure for cryptogenic stroke: The
REDUCE Trial
* Hugo Torres, MD, MPH
* Chapter 4 Thrombolysis timing in acute ischemic stroke: The ECASS III
Trial
* Jillian M. Berkman, MD and Mark Etherton, MD, PhD
* Chapter 5 Symptom-triggered vs fixed-schedule benzodiazepines for
alcohol withdrawal
* Rahul B. Ganatra, MD, MPH
* Chapter 6 Education and naloxone distribution to prevent opioid
overdoses
* Victoria D. Powell, MD and Pooja Lagisetty, MD
* SECTION 2: CARDIOLOGY
* Chapter 7 Peri-operative risk for myocardial infarction or cardiac
arrest
* Jeffrey L. Greenwald, MD
* Chapter 8 Perioperative beta blockers for non-cardiac surgery
* Jeffrey L. Greenwald, MD
* Chapter 9 Heparin vs. enoxaparin for unstable coronary artery
disease: The ESSENCE trial
* Bradford A. Hilson, MD
* Chapter 10 Early invasive management for non-ST segment elevation
acute coronary syndrome: The TACTICS-TIMI-18 Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 11 Dual antiplatelet therapy for non-ST segment elevation
acute coronary syndromes: The Cure Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 12 Intensive vs moderate-intensity statins after acute
coronary syndromes: The PROVE IT-TIMI 22 Trial
* Nilay K. Patel, MD
* Chapter 13 Loop diuretics for decompensated heart failure: The DOSE
Study
* Debbie Lin Teodorescu, MD, MEng, AM and Hugo Torres, MD, MPH
* Chapter 14 Angiotensin receptor-neprilysin inhibition in heart
failure: The PARADIGM-HF Trial
* Peyton Hanson, MD and Kathleen M. Finn MD, MPhil
* Chapter 15 Estimating risk of stroke in atrial fibrillation: The
CHADS2 Trial
* Yichi Zhang MD, MBA, Christopher S. Schenck, MD, and David M.
Dudzinski, MD
* Chapter 16 Apixaban vs. warfarin for atrial fibrillation: The
ARISTOTLE trial
* Priyank Jain, MBBS
* SECTION 3: PULMONOLOGY and CRITICAL CARE
* Chapter 17 Procalcitonin-guided antibiotic use in lower respiratory
tract infection
* Philipp Schuetz, MD, MPH
* Chapter 18 Early discontinuation of antibiotics for
community-acquired pneumonia
* Kathy May Tran, MD
* Chapter 19 Glucocorticoids in exacerbations of chronic obstructive
pulmonary disease: The REDUCE Trial
* Mobola Campbell, MD, MPH, MEd and Jeffrey L. Greenwald, MD
* Chapter 20 Noninvasive ventilation for exacerbations of chronic
obstructive pulmonary disease
* Raymond C. Parrish II, MD
* Chapter 21 Clinical criteria and D-dimer to exclude pulmonary
embolism: The Wells Criteria
* Jeffrey L. Greenwald, MD
* Chapter 22 Point-of-care ultrasound in acute respiratory failure: The
BLUE Protocol
* Thomas F. Heyne, MD, MSt and Kathy May Tran, MD
* Chapter 23 Low tidal volume ventilation in acute respiratory distress
syndrome: The ARMA Trial
* Raymond C. Parrish II, MD
* Chapter 24 Fluid management in acute respiratory distress syndrome:
The FACTT Trial
* Dominik J. Hoechter, MD
* Chapter 25 Dopamine vs. norepinephrine for shock: The SOAP II Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 26 Protocol-based care for septic shock: The ProCESS Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 27 Targeted temperature management after cardiac arrest: The
TTM Trial
* Christy N. Taylor, MD, MPH and Jonathan Ludmir, MD
* SECTION 4: GASTROENTEROLOGY
* Chapter 28 Fecal transplant for recurrent Clostridiodes difficile
infection
* Farrin A. Manian, MD, MPH
* Chapter 29 Antibiotic prophylaxis in cirrhosis and upper
gastrointestinal bleeding
* Farrin A. Manian, MD, MPH
* Chapter 30 Endoscopic variceal ligation and nadolol to prevent
variceal rebleeding
* Rahul B. Ganatra, M.D., MPH
* Chapter 31 Albumin for spontaneous bacterial peritonitis in cirrhosis
* Bradford A. Hilson, MD
* SECTION 5: HEMATOLOGY and ONCOLOGY
* Chapter 32 Risk for venous thromboembolism in hospitalized patients:
The Padua Prediction Score
* Rahul B. Ganatra, MD, MPH
* Chapter 33 Low-molecular weight vs. unfractionated heparin for
pulmonary embolism
* William C. Hillmann, MD, MS
* Chapter 34 Low-molecular weight heparin vs. oral vitamin K antagonist
for cancer-associated venous thromboembolism: The CLOT Trial
* Marko Velimirovic, MD, MMSc and Hugo Torres, MD, MPH
* Chapter 35 Perioperative anticoagulation for atrial fibrillation: The
BRIDGE Trial
* Priyank Jain, MBBS
* Chapter 36 Bleeding risk from anticoagulation in atrial fibrillation:
HAS-BLED
* Jeffrey L. Greenwald, MD
* Chapter 37 Transfusion thresholds in critically ill patients: The
TRICC Trial
* Jeffrey L. Greenwald, MD
* Chapter 38 4 T's Score to exclude heparin-induced thrombocytopenia
* Jeffrey L. Greenwald, MD
* Chapter 39 Early palliative care for metastatic cancer
* Mobola Campbell, MD, MPH, MEd and Kathy May Tran, MD
* SECTION 6: FLUIDS, NUTRITION, and METABOLISM
* Chapter 40 Timing of parenteral nutrition in critically ill patients:
The EPaNIC Study
* Mobola Campbell, MD, MPH, MEd and Katharine E. Black, M.D.
* Chapter 41 Early nasoenteric tube feeding in acute pancreatitis: The
PYTHON Trial
* Margaret M. Chapman, MD
* Chapter 42 Glucose control in critically ill patients: The NICE-SUGAR
Trial
* Hugo Torres, MD, MPH
* Chapter 43 Zoledronic acid after hip fracture: The HORIZON-RFT Trial
* Hugo Torres, MD, MPH and Kathy May Tran, MD
* SECTION 7: HOSPITAL SYSTEMS and OPERATIONS
* Chapter 44 Unconscious bias in referrals for cardiac catheterization
* William J. Tate, MD and Sherri-Ann M. Burnett-Bowie, MD, MPH
* Chapter 45 Replacing indwelling urinary catheters for urinary tract
infection
* Hugo Torres, MD, MPH
* Chapter 46 Financial impact of healthcare-associated infections
* Marc Philip T. Pimentel, MD, MPH
* Chapter 47 Pharmacist-guided medication reconciliation to reduce
readmissions
* Hugo Torres, MD, MPH
* Chapter 48 Patient-targeted discharge education to prevent heart
failure readmissions
* Aditya Achanta, MD and Jason H. Wasfy, MD, MPhil
* Chapter 49 Identifying preventable 30-day hospital readmissions
* Hugo Torres, MD, MPH and Jeffrey L. Greenwald, MD
* Chapter 50 Effect of hospitalist care on medical utilization
* Anand Kartha, MD, MS
* Chapter 1 Detecting delirium: The CAM study
* Benjamin P. Geisler, MD, MPH
* Chapter 2 Delirium prevention in older hospitalized patients: The
Elder Life Program Trial
* Mobola Campbell, MD, MPH, MEd
* Chapter 3 Patent foramen ovale closure for cryptogenic stroke: The
REDUCE Trial
* Hugo Torres, MD, MPH
* Chapter 4 Thrombolysis timing in acute ischemic stroke: The ECASS III
Trial
* Jillian M. Berkman, MD and Mark Etherton, MD, PhD
* Chapter 5 Symptom-triggered vs fixed-schedule benzodiazepines for
alcohol withdrawal
* Rahul B. Ganatra, MD, MPH
* Chapter 6 Education and naloxone distribution to prevent opioid
overdoses
* Victoria D. Powell, MD and Pooja Lagisetty, MD
* SECTION 2: CARDIOLOGY
* Chapter 7 Peri-operative risk for myocardial infarction or cardiac
arrest
* Jeffrey L. Greenwald, MD
* Chapter 8 Perioperative beta blockers for non-cardiac surgery
* Jeffrey L. Greenwald, MD
* Chapter 9 Heparin vs. enoxaparin for unstable coronary artery
disease: The ESSENCE trial
* Bradford A. Hilson, MD
* Chapter 10 Early invasive management for non-ST segment elevation
acute coronary syndrome: The TACTICS-TIMI-18 Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 11 Dual antiplatelet therapy for non-ST segment elevation
acute coronary syndromes: The Cure Trial
* Cian P. McCarthy, MB, BCH, BAO, SM
* Chapter 12 Intensive vs moderate-intensity statins after acute
coronary syndromes: The PROVE IT-TIMI 22 Trial
* Nilay K. Patel, MD
* Chapter 13 Loop diuretics for decompensated heart failure: The DOSE
Study
* Debbie Lin Teodorescu, MD, MEng, AM and Hugo Torres, MD, MPH
* Chapter 14 Angiotensin receptor-neprilysin inhibition in heart
failure: The PARADIGM-HF Trial
* Peyton Hanson, MD and Kathleen M. Finn MD, MPhil
* Chapter 15 Estimating risk of stroke in atrial fibrillation: The
CHADS2 Trial
* Yichi Zhang MD, MBA, Christopher S. Schenck, MD, and David M.
Dudzinski, MD
* Chapter 16 Apixaban vs. warfarin for atrial fibrillation: The
ARISTOTLE trial
* Priyank Jain, MBBS
* SECTION 3: PULMONOLOGY and CRITICAL CARE
* Chapter 17 Procalcitonin-guided antibiotic use in lower respiratory
tract infection
* Philipp Schuetz, MD, MPH
* Chapter 18 Early discontinuation of antibiotics for
community-acquired pneumonia
* Kathy May Tran, MD
* Chapter 19 Glucocorticoids in exacerbations of chronic obstructive
pulmonary disease: The REDUCE Trial
* Mobola Campbell, MD, MPH, MEd and Jeffrey L. Greenwald, MD
* Chapter 20 Noninvasive ventilation for exacerbations of chronic
obstructive pulmonary disease
* Raymond C. Parrish II, MD
* Chapter 21 Clinical criteria and D-dimer to exclude pulmonary
embolism: The Wells Criteria
* Jeffrey L. Greenwald, MD
* Chapter 22 Point-of-care ultrasound in acute respiratory failure: The
BLUE Protocol
* Thomas F. Heyne, MD, MSt and Kathy May Tran, MD
* Chapter 23 Low tidal volume ventilation in acute respiratory distress
syndrome: The ARMA Trial
* Raymond C. Parrish II, MD
* Chapter 24 Fluid management in acute respiratory distress syndrome:
The FACTT Trial
* Dominik J. Hoechter, MD
* Chapter 25 Dopamine vs. norepinephrine for shock: The SOAP II Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 26 Protocol-based care for septic shock: The ProCESS Trial
* Benjamin P. Geisler, MD, MPH
* Chapter 27 Targeted temperature management after cardiac arrest: The
TTM Trial
* Christy N. Taylor, MD, MPH and Jonathan Ludmir, MD
* SECTION 4: GASTROENTEROLOGY
* Chapter 28 Fecal transplant for recurrent Clostridiodes difficile
infection
* Farrin A. Manian, MD, MPH
* Chapter 29 Antibiotic prophylaxis in cirrhosis and upper
gastrointestinal bleeding
* Farrin A. Manian, MD, MPH
* Chapter 30 Endoscopic variceal ligation and nadolol to prevent
variceal rebleeding
* Rahul B. Ganatra, M.D., MPH
* Chapter 31 Albumin for spontaneous bacterial peritonitis in cirrhosis
* Bradford A. Hilson, MD
* SECTION 5: HEMATOLOGY and ONCOLOGY
* Chapter 32 Risk for venous thromboembolism in hospitalized patients:
The Padua Prediction Score
* Rahul B. Ganatra, MD, MPH
* Chapter 33 Low-molecular weight vs. unfractionated heparin for
pulmonary embolism
* William C. Hillmann, MD, MS
* Chapter 34 Low-molecular weight heparin vs. oral vitamin K antagonist
for cancer-associated venous thromboembolism: The CLOT Trial
* Marko Velimirovic, MD, MMSc and Hugo Torres, MD, MPH
* Chapter 35 Perioperative anticoagulation for atrial fibrillation: The
BRIDGE Trial
* Priyank Jain, MBBS
* Chapter 36 Bleeding risk from anticoagulation in atrial fibrillation:
HAS-BLED
* Jeffrey L. Greenwald, MD
* Chapter 37 Transfusion thresholds in critically ill patients: The
TRICC Trial
* Jeffrey L. Greenwald, MD
* Chapter 38 4 T's Score to exclude heparin-induced thrombocytopenia
* Jeffrey L. Greenwald, MD
* Chapter 39 Early palliative care for metastatic cancer
* Mobola Campbell, MD, MPH, MEd and Kathy May Tran, MD
* SECTION 6: FLUIDS, NUTRITION, and METABOLISM
* Chapter 40 Timing of parenteral nutrition in critically ill patients:
The EPaNIC Study
* Mobola Campbell, MD, MPH, MEd and Katharine E. Black, M.D.
* Chapter 41 Early nasoenteric tube feeding in acute pancreatitis: The
PYTHON Trial
* Margaret M. Chapman, MD
* Chapter 42 Glucose control in critically ill patients: The NICE-SUGAR
Trial
* Hugo Torres, MD, MPH
* Chapter 43 Zoledronic acid after hip fracture: The HORIZON-RFT Trial
* Hugo Torres, MD, MPH and Kathy May Tran, MD
* SECTION 7: HOSPITAL SYSTEMS and OPERATIONS
* Chapter 44 Unconscious bias in referrals for cardiac catheterization
* William J. Tate, MD and Sherri-Ann M. Burnett-Bowie, MD, MPH
* Chapter 45 Replacing indwelling urinary catheters for urinary tract
infection
* Hugo Torres, MD, MPH
* Chapter 46 Financial impact of healthcare-associated infections
* Marc Philip T. Pimentel, MD, MPH
* Chapter 47 Pharmacist-guided medication reconciliation to reduce
readmissions
* Hugo Torres, MD, MPH
* Chapter 48 Patient-targeted discharge education to prevent heart
failure readmissions
* Aditya Achanta, MD and Jason H. Wasfy, MD, MPhil
* Chapter 49 Identifying preventable 30-day hospital readmissions
* Hugo Torres, MD, MPH and Jeffrey L. Greenwald, MD
* Chapter 50 Effect of hospitalist care on medical utilization
* Anand Kartha, MD, MS
